INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2024

Shots: The second quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Vertex’ acquisition of Alpine Immune Sciences for ~$4.9B This quarter also showcased multiple clinical trial results including Moderna’s P-III Study Data of mRNA-1283 Vaccine to Prevent COVID-19…

July 2, 2024

New Drug Designations – May 2024

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 12 small molecules, 7 biologics, 9 cell & gene therapies, 1 vaccine, 1 peptide, 1 RNA candidate, 1 recombinant fusion protein, 1 imaging agent and 6 devices This…

June 25, 2024

Insights+: EMA Marketing Authorization of New Drugs in May 2024

Shots: The EMA approved or granted Positive Opinions to 5 Biologics and 7 New Chemical Entities in May 2024, leading to treatments for patients and advances in the healthcare industry The major highlighted drugs were BMS’ Opdivo + cisplatin & gemcitabine to treat Urothelial Carcinoma and Takeda’s ADAMTS13 for the treatment cTTP PharmaShots has compiled…

June 20, 2024

Insights+: The US FDA New Drug Approvals in May 2024

Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of May 2024 The US FDA approved a total of 3 new drugs including 2 new molecular entities and 1 biologic leading to treatments for patients and advances in the healthcare industry The major highlighted drug was Amgen’s Imdelltra for the treatment…

June 18, 2024

Know Your Investor (June Edition): Google Ventures

Shots: Google Ventures is an investment arm of Alphabet Inc. That invests profusely in seed-stage companies ranging from software and internet to healthcare, life sciences, and artificial intelligence among others Ever since 2016, GV pivoted to focusing on established companies. The company manages assets worth $10B and 400 active portfolio companies spanning across North America…

June 13, 2024

Disease of the Month – Fabry Disease

Shots: Fabry disease is a rare inherited neurological disorder that affects the body's ability to break down lipids into smaller components In this reprise of our Disease of the Month report, we bring an illuminating account of Fabry Disease with deep dive analysis of epidemiology, market size, disease management, available therapies, patient advocacy groups, and…

June 12, 2024

Insights+ Key Biosimilars Events of May 2024

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   During May, Teva & Alvotech launched Simlandi injection Treat Multiple Indications. Our…

June 4, 2024

New Drug Designations – April 2024

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 11 small molecules, 7 biologics, 7 cell & gene therapies, 1 antiviral, 1 peptide and 3 devices Lisata Therapeutics’ LSTA1 received ODD this month and was granted with…

May 30, 2024

Know Your Investor (May Edition): Alexandria Venture Investment

Shots: In the May Edition of the Know Your Investor series, we are focussing on Alexandria Venture Investments, an integral part of Alexandria Real Estate Equities In 2023, Alexandria Venture Investments invested in 24 companies; 5, 8, 5 & 6 every quarter across 2023 respectively For a detailed report on all the investments, reach out…

May 28, 2024

Insights+: EMA Marketing Authorization of New Drugs in April 2024

Shots: The EC approved 10 New Chemical Entities in April 2024, leading to treatments for patients and advances in the healthcare industry In April 2024, the major highlighted drugs were Takeda’s Fruzaqla to treat Adults with mCRC and Johnson & Johnson’s Rybrevant for the treatment NSCLC PharmaShots has compiled a list of 5 drugs that have received positive…

May 21, 2024